Related posts:

1. Modern Treatments For GERD Effective At Achieving Long-Term Remission For Most Patients In an evaluation of contemporary antireflux therapies for chronic gastroesophageal reflux disease (GERD), most patients who received treatment with either the proton pump inhibitor esomeprazole or laparoscopic antireflux surgery achieved and remained in disease remission for 5 years, according to a study in the May 18 issue of JAMA....
2. California Share of Cost, Food Dye Ban Implemented Or Considered By Some Health Authorities After Cancer And Hyperactivity Link Found California Share of Cost, Food Dye Ban Implemented Or Considered By Some Health Authorities After Cancer And Hyperactivity Link Found: After new scientific evidence revealed a possible link between food dyes and childhood cancer and hyperactivity, Australian food authorities are reported to be considering banning food colorings from breakfast cereals and confectionary items. The research […]...
3. Share of Cost, Chronic Gastroesophageal Reflux Disease – Medication And Surgery Equally Effective Laparoscopic antireflux surgery or taking proton pump inhibitor esomeprazole for chronic GERD (chronic gastroesophageal reflux disease) were both found to result in similar rates of disease remission of five years, researchers from Nantes University, France, reported in JAMA (Journal of the American Medical Association)....
4. Share of Cost, Allergy Shots Are Helpful For Some Asthmatics, Risky For Others Allergy shots can reduce symptoms of asthma, use of inhaled medications and allergy-related asthma attacks, confirms an updated review of studies. Yet, the treatment can also cause systemic side effects that range from a stuffy nose to fatal anaphylactic shock....
5. Share of Cost, Esophageal Cancer Risk Lower Than Expected For GERD Patients Share of Cost, The risk of esophageal cancer among patients who suffer from gastroesophageal reflux disease (GERD) is not as high as many may think, according to new research from University of Michigan gastroenterologists. GERD is considered a relative risk for developing esophageal adenocarcinoma, but the absolute risk is not known, says Joel Rubenstein, M.D., […]...
6. Share of Cost, For Acid Reflux Disease Patients, Esophageal Cancer Risk Lower Than Expected Share of Cost, The risk of esophageal cancer among patients who suffer from gastroesophageal reflux disease (GERD) is not as high as many may think, according to new research from University of Michigan gastroenterologists. GERD is considered a relative risk for developing esophageal adenocarcinoma, but the absolute risk is not known, says Joel Rubenstein, M.D., […]...
7. Share of Cost, Federal Digest Washington Post FDA considers revoking approval of Avastin for advanced breast cancer – Rob Stein reports on agency’s decision after follow up studies on high-cost drug that won fast-track approval show little if any benefit and potentially dangerous side-effects; cancer activists split on decision, which some see as harbinger of cost consideration under new health […]...
8. Extended Funding For GLong-Standing Investigation Into Regulation Ofastrointestinal Eosinophils Marc E. Rothenberg, M.D., Ph.D., director of the Division of Allergy and Immunology at Cincinnati Children’s, has received an NIH MERIT Award to extend funding of his long-standing investigation into “Regulation of Gastrointestinal Eosinophils.” Dr…...
9. When Budgets Are Tight, There Are Better Options Than Colonoscopies For Colorectal Cancer Screening [Web First] A critical challenge facing cancer screening programs, particularly those aimed at uninsured people with low incomes, is choosing the screening test that makes the most efficient use of limited budgets. For colorectal cancer screening, there is growing momentum to use colonoscopy, which is an expensive test. In this study, we modeled scenarios to assess whether […]...
10. Researchers Find More Evidence That Malaria Drug Could Help Combat Cancer, And That Breaks From Treatment Could Improve Results Scientists investigating the cancer-fighting properties of artesunate a drug commonly used to treat malaria have found early evidence that combining it with an existing cancer drug has the potential to make each drug more effective than when used alone. They also found that regular treatment breaks could improve success levels. The findings, recently published in […]...
11. Asthma And Eczema Sufferers Have A Lower Risk Of Developing A Cancer Men who had a history of asthma or eczema generally had a lower risk of developing cancer, according to a study carried out by researchers at INRS Institut Armand-Frappier, the Research Centre of the Centre hospitalier de l’Université de Montréal, and McGill University…...
12. Share of Cost, The Number Of U.S. Adults Treated For Diabetes More Than Doubled Between 1996 And 2007 Approximately 19 million U.S. adults reported receiving treatment for diabetes in 2007, more than double the 9 million who said they received care in 1996, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. AHRQ also found that between 1996 and 2007: — The number of people age 65 […]...
13. Share of Cost, The Importance Of Timing In Ensuring Healthy Brain Development Share of Cost, The Importance Of Timing In Ensuring Healthy Brain Development...
14. Homing In On Genetic Signature Of Esophageal Cancer University of Rochester Medical Center researchers have pinpointed two genes that are amplified in the worst cases of esophageal cancer, providing data to support a new investigational treatment that targets those same genes. The study, led by Tony Godfrey, Ph.D., a research associate professor of Surgery at the James P....
15. Seaside Therapeutics Initiates Phase 2b Study Of STX209 In Autism Spectrum Disorders Seaside Therapeutics, Inc. announced today the initiation of a randomized, double-blind, placebo-controlled Phase 2b study to evaluate the effects of STX209 (arbaclofen) on social impairment in children, adolescents and adults (ages 5 to 21) with autism spectrum disorders (ASD). The Company announced positive results from an open-label Phase 2a study of STX209 in September of […]...